REGENXBIO CEO and leadership

Ken Mills is the founding President and Chief Executive Officer of REGENXBIO. Prior to REGENXBIO, Mr. Mills was the Chief Financial Officer and Vice President of Business Development at Meso Scale Diagnostics, a privately held life sciences company. There, he served as a member of the founding management team, and worked to establish the company's operations and ongoing business strategy. In this position, Mr. Mills supervised all company activities, including direct management of corporate and business development, strategic planning, finance and accounting activities. Prior to Meso Scale Diagnostics, he was Director of Business Development for IGEN International, a medical diagnostics company. Mr. Mills received an S.B. in chemistry from the Massachusetts Institute of Technology.

James M. Wilson, M.D., Ph.D. has been named its Chief Scientific Advisor, effective immediately. Dr. Wilson is also the director of the Gene Therapy Program and professor of Pathology and Laboratory Medicine at the Perelman School of Medicine at the University of Pennsylvania (Penn).

Curran M. Simpson is the Senior Vice President of Product Development and Chief Technology Officer at REGENXBIO. Prior to joining REGENXBIO, Mr. Simpson was the Head of North American Supply Chain and Interim Chief Operating Officer and Integration Lead at GlaxoSmithKline and the Human Genome Sciences division of GlaxoSmithKline. Mr. Simpson earlier served as Senior Vice President of Operations and Vice President of Manufacturing Operations at Human Genome Sciences.

Patrick Christmas is a Senior VP/Chief Legal Officer at REGENXBIO INC.. He has worked as Senior VP/General Counsel at REGENXBIO INC., VP/General Counsel at K-V Pharmaceutical Co., and General Counsel at BIOVERIS CORP. Patrick attended Boston College and University of Notre Dame.

A licensed physician with over 20 years of Pharma/Biotech experience in roles of increasing responsibility (now Chief Medical Officer of REGENXBIO Inc, previously Chief Medical Officer at Aerpio, Amakem and ThromboGenics)Employers prior to Amakem: ThromboGenics, Boehringer Ingelheim, Organon, QuintilesSpecialties: Clinical Development/Regulatory/Medical Affairs Extensive experience in following therapeutic areas: Ophthalmology, Cardiovascular, CNS, Oncology

Ken Mills is the founding President and Chief Executive Officer of REGENXBIO. Prior to REGENXBIO, Mr. Mills was the Chief Financial Officer and Vice President of Business Development at Meso Scale Diagnostics, a privately held life sciences company. There, he served as a member of the founding management team, and worked to establish the company's operations and ongoing business strategy. In this position, Mr. Mills supervised all company activities, including direct management of corporate and business development, strategic planning, finance and accounting activities. Prior to Meso Scale Diagnostics, he was Director of Business Development for IGEN International, a medical diagnostics company. Mr. Mills received an S.B. in chemistry from the Massachusetts Institute of Technology.

James M. Wilson, M.D., Ph.D. has been named its Chief Scientific Advisor, effective immediately. Dr. Wilson is also the director of the Gene Therapy Program and professor of Pathology and Laboratory Medicine at the Perelman School of Medicine at the University of Pennsylvania (Penn).

Ken Mills is the founding President and Chief Executive Officer of REGENXBIO. Prior to REGENXBIO, Mr. Mills was the Chief Financial Officer and Vice President of Business Development at Meso Scale Diagnostics, a privately held life sciences company. There, he served as a member of the founding management team, and worked to establish the company's operations and ongoing business strategy. In this position, Mr. Mills supervised all company activities, including direct management of corporate and business development, strategic planning, finance and accounting activities. Prior to Meso Scale Diagnostics, he was Director of Business Development for IGEN International, a medical diagnostics company. Mr. Mills received an S.B. in chemistry from the Massachusetts Institute of Technology.

James M. Wilson, M.D., Ph.D. has been named its Chief Scientific Advisor, effective immediately. Dr. Wilson is also the director of the Gene Therapy Program and professor of Pathology and Laboratory Medicine at the Perelman School of Medicine at the University of Pennsylvania (Penn).